X

Trial Profile

A phase 2a clinical study of ACD 440 in the patients with peripheral Neuropathic-pain

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACD 440 (Primary)
Indications Neuropathic pain
Focus Therapeutic Use

Most Recent Events

25 May 2022 According to an AlzeCure media release, company has received approval from the regulatory authorities in Sweden to initiate this study. Company expect to initiate the study soon and present results in 2023
11 Feb 2022 New trial record
08 Feb 2022 According to a AlzeCure media release, company has received a response from the US Food and Drug Administration (FDA) regarding the preIND application that was submitted prior to this planned study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com